Multiple Doses of Anti-NOGO A in Relapsing Forms of Multiple Sclerosis

Inclusion Criteria: * Diagnosed with a relapsing form of MS . * Using one of the following ongoing MS treatment strategies, defined as 1. Currently receiving Beta-interferon/Copaxone for treatment of MS and have been receiving the current course of therapy for 3 or more months prior to screening, OR 2. Not currently receiving disease modifying therapies for treatment of MS, and has not received such therapies for at least 3 months prior to screening. * Demonstrated clinical activity in 2 years prior to screening, whilst receiving current/previous treatment regimen or prior to any treatment regimen * Expanded Disability Status Scale (EDSS) score ≤6.0 at either the screening or baseline visit. * Male or female between 18 and 60 years of age inclusive, at the time of signing the informed consent. * Body weight equal to or greater than: 50 kilogrammes Exclusion Criteria: * Complications/History of other diseases that may impact on safety of patients enroling into the study. * Liver function test outside normal range for patient population * Treatment with methylprednisolone or any other systemic steroid, for a relapse or otherwise, within 30 days of screening * Treatment in the past 6 months with any of the following agents: Fingolimod (Gilenya), methotrexate, mitoxantrone, azathioprine, or other small molecule immunosuppressants. * History of anaphilaxis to protein based therapeutics or mono-clonal antibodies. * Positive result for Hapatitis B, HIV, and/or drugs of abuse, or excessive alcohol consumption. * Not able to undergo MRI scanning safely, or Gadolinium (contrast enhancing agents) during MRI. * Other significant infections e.g. Tuberculosis.